

	Document ID	Issue Date	Pages	Title	Current OR
1	US 590408 A	20000718	41	Use of polymerized lipid diagnostic agents	424/450
2	US 6090800 A	20000718	58	Lipid soluble steroid prodrugs	514/180
3	US 5965131 A	19991012	15	Delivery of diagnostic and therapeutic agents to a target site	424/133.1
4	US 5955605 A	19990921	82	Biotinidase resistant biotin-DOTA conjugates	540/474
5	US 5914312 A	19990622	46	Pretargeting methods and compounds	514/8

	Document ID	Issue Date	Pages	Title	Current OR
6	US 5914095 A	19990622	14	Polychelants containing amide bonds	424/1.65
7	US 5911969 A	19990615	46	Pretargeting protocols for enhanced localization of active agents to target sites	424/1.11
8	US 5851526 A	19981222	22	Methods of treating colon cancer utilizing tumor-specific antibodies	424/156.1
9	US 5847121 A	19981208	67	Production of nitro-benzyl-dota via direct peptide cyclization	540/474
10	US 5807879 A	19980915	21	Biotinidase-resistant biotinylated compound and methods of use thereof	514/387
11	US 5679810 A	19971021	20	Linear oligomeric polychelant compounds	556/1

	Document ID	Issue Date	Pages	Title	Current OR
12	US 5672334 A	19970930	75	In vivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans	424/9.34
13	US 5630996 A	19970520	80	Two-step pretargeting methods using improved biotin-active agent conjugates	424/1.49
14	US 5364613 A	19941115	16	Polychelants containing macrocyclic chelant moieties	424/9.3
15	US 5283342 A	19940201	15	Biotinylated small molecules	548/304.1

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal208dxj

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Feb	2	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Dec	17	Expanded CAPLUS Coverage of US, Japanese, WIPO, EPO, and German patents
NEWS	3	Feb	1	Addition of Machine-Translated Abstracts to CAPLUS
NEWS	4	Feb	28	Patent Information Now Searchable in CAOLD
NEWS	5	May		RN CROSSOVER AND ANSWER SIZE LIMITS INCREASED
NEWS	6	May	22	CITED REFERENCES NOW AVAILABLE IN CAPLUS AND CA FILE
NEWS	7	May	22	POSTPROCESSING OF SEARCH RESULTS MAY BE AFFECTED BY ADDITION OF CITED REFERENCES TO CAPLUS, CA, REGISTRY, CASREACT, MARPAT, and MARPATPREV
NEWS	8	Jun	2	KOREAN PATENTS NOW IN CAS DATABASES
NEWS	9	Jun	20	WIPO/PCT Patents Fulltext Database now on STN
NEWS	10	Jun	28	CAS covers Web-distributed preprints
NEWS	11	Jul	7	Patent Full-text Cluster, PNTTEXT, introduced
NEWS	12	Jul	27	EUROPATFULL - loading of backlog data
NEWS	13	Jul	27	MORE FREQUENT UPDATES FOR DERWENT WORLD PATENTS INDEX IN 2000
NEWS	14	Jul	27	Derwent Journal Of Synthetic Methods Reloaded with New Data
NEWS	15	Jul	27	DERWENT WORLD PATENTS INDEX: FAST TRACK RELEASE OF EQUIVALENT PATENTS
NEWS	16	Aug	21	Instant Access to FDA Regulatory Information with DIOGENES
NEWS	17	Aug	21	CAS patent coverage expanded
NEWS EXPRESS				FREE UPGRADE 5.0D FOR STN EXPRESS 5.0 WITH DISCOVER! (WINDOWS) NOW AVAILABLE
NEWS HOURS				STN Operating Hours Plus Help Desk Availability
NEWS INTER				General Internet Information
NEWS LOGIN				Welcome Banner and News Items
NEWS PHONE				Direct Dial and Telecommunication Network Access to STN
NEWS WWW				CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:43:33 ON 22 AUG 2000

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'REGISTRY' ENTERED AT 08:43:49 ON 22 AUG 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 21 AUG 2000 HIGHEST RN 286930-05-0
DICTIONARY FILE UPDATES: 21 AUG 2000 HIGHEST RN 286930-05-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 11, 2000

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT
for details.

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading c:\stnexp4\queries\405e.str

L1 STRUCTURE UPLOADED


=> que L1

L2 QUE L1

=> d

L2 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.
 L2 QUE ABB=ON PLU=ON L1

=> s 12

SAMPLE SEARCH INITIATED 08:44:15 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 42 TO ITERATE

100.0% PROCESSED 42 ITERATIONS
 SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 452 TO 1228
 PROJECTED ANSWERS: 0 TO 0

L3 0 SEA SSS SAM L1

=> s 12 full

FULL SEARCH INITIATED 08:44:24 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 934 TO ITERATE

100.0% PROCESSED 934 ITERATIONS
 SEARCH TIME: 00.00.01

0 ANSWERS

L4 0 SEA SSS FUL L1

=> e dota/cn

E1	1	DOSULEPINE/CN
E2	1	DOSULFIN/CN
E3	1	DOTA/CN
E4	1	DOTAN/CN
E5	1	DOTAP/CN
E6	1	DOTAP CHLORIDE/CN
E7	1	DOTAREM/CN
E8	1	DOTARIZINE/CN
E9	1	DOTB/CN
E10	1	DOTC/CN
E11	1	DOTCI/CN
E12	1	DOTEFONIUM BROMIDE/CN

=> s e3

L5 1 DOTA/CN

=> d

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2000 ACS
RN 60239-18-1 REGISTRY
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA
INDEX

NAME)

OTHER NAMES:

CN 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid

CN DOTA

FS 3D CONCORD

DR 105416-43-1

MF C16 H28 N4 O8

CI COM

LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOTECHNO, CA, CANCERLIT,


CAPLUS,

CASREACT, CEN, CHEMCATS, CIN, CSCHM, EMBASE, GHELIN*, MEDLINE,

PROMT,

TOXLINE, TOXLIT, USPATFULL

(*File contains numerically searchable property data)



234 REFERENCES IN FILE CA (1967 TO DATE)
138 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
236 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> e dota

E1	1	DOSULFIN/BI
E2	25	DOT/BI
E3	7	DOTA/BI
E4	1	DOTA0/BI
E5	1	DOTA0, TYR3/BI
E6	4	DOTAN/BI
E7	2	DOTAP/BI
E8	1	DOTAREM/BI
E9	1	DOTARIZINE/BI
E10	1	DOTB/BI
E11	1	DOTC/BI
E12	1	DOTCI/BI

=> s e3

L6 7 DOTA/BI

=> d 1-

YOU HAVE REQUESTED DATA FROM 7 ANSWERS - CONTINUE? Y/(N):y

L6 ANSWER 1 OF 7 REGISTRY COPYRIGHT 2000 ACS
 RN 203709-53-9 REGISTRY
 CN DBA (Chryselepidomonas dendroepidota strain CCM293 gene rbcl fragment) (9CI) (CA INDEX NAME)

OTHER NAMES:
 CN GenBank AF015570
 FS NUCLEIC ACID SEQUENCE
 MF Unspecified
 CI MAN
 SR GenBank
 LC STN Files: CA, CAPLUS, GENBANK, TOXLIT

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 *** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
 1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L6 ANSWER 2 OF 7 REGISTRY COPYRIGHT 2000 ACS
 RN 160872-57-1 REGISTRY
 CN Protein (Legionella pneumophila strain LP02 gene dota) (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE
 MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXLIT

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 *** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
 1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L6 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2000 ACS
 RN 159072-97-6 REGISTRY
 CN DBA (Legionella pneumophila strain LP02 gene dota and gene sbpA and gene dlpA plus flanks) (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Deoxyribonucleic acid (Legionella pneumophila strain LP02 gene dota and gene sbpA and gene dlpA plus 5'- and 3'-flanking region fragment)

OTHER NAMES:
 CN GenBank U07940
 FS NUCLEIC ACID SEQUENCE
 MF Unspecified
 CI MAN
 SR GenBank
 LC STN Files: CA, CAPLUS, GENBANK, TOXLIT


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 *** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
 1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L6 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2000 ACS
 RN 99328-55-9 REGISTRY
 * Use of this CAS Registry Number alone as a search term in other STN files may result in incomplete search results. For additional information, enter
 HELP
 RN* at an online arrow prompt (=>).
 CN Licorice, Glycyrrhiza lepidota, ext., calcium salts (CA INDEX NAME)
 MF Unspecified
 CI MAN, CTS
 SR Commission of European Communities
 LC STN Files: CHEMLIST
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


L6 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2000 ACS
 RN 92943-93-6 REGISTRY
 CN D-Glucitol, 1-deoxy-1-(methylamino)-, [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(4-)-.kappa.N1,.kappa.N4,.kappa.N7,.kappa.N10,.kappa.O1,.kappa.O4,.kappa.O7,.kappa.O10]gadolinate(1-) (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 1,4,7,10-Tetraazacyclododecane, D-glucitol deriv.
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, gadolinium complex
 CN D-Glucitol, 1-deoxy-1-(methylamino)-, [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(4-)-N1,N4,N7,N10,O1,O4,O7,O10]gadolinate(1-)
 CN Gadolinate(1-), [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(4-)-N1,N4,N7,N10,O1,O4,O7,O10]-, hydrogen, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1)
 CN Gadolinate(1-), [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(4-)-.kappa.N1,.kappa.N4,.kappa.N7,.kappa.N10,.kappa.O1,.kappa.O4,.kappa.O7,.kappa.O10]-, hydrogen, compd. with 1-deoxy-1-(methylamino)-D-glucitol (1:1)
 (9CI)
 OTHER NAMES:
 CN Gadolinium-DOTA meglumine
 CN Gd-DOTA meglumine
 FS STEREOSEARCH
 DR 205589-93-1
 MF C16 H24 Gd N4 O8 . C7 H17 N O5 . H
 LC STN Files: BIOSIS, CA, CAPLUS, EMBASE, TOXLIT, USPATFULL
 CM 1
 CRN 72573-82-1 (83678-67-5)
 CMF C16 H24 Gd N4 O8 . H
 CCI CCS

L6 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2000 ACS
 RN 83678-67-5 REGISTRY
 CN Gadolinate(1-), [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(4-)-.kappa.N1,.kappa.N4,.kappa.N7,.kappa.N10,.kappa.O1,.kappa.O4,.kappa.O7,.kappa.O10]- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 1,4,7,10-Tetraazacyclododecane, gadolinate(1-) deriv.
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, gadolinium complex
 CN Gadolinate(1-), [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(4-)-N1,N4,N7,N10,O1,O4,O7,O10]-
 OTHER NAMES:
 CN Dotarem
 CN Gadolinium-DOTA
 CN Gadoterate
 CN Gd-DOTA
 MF C16 H24 Gd N4 O8
 CI CCS, COM
 LC STN Files: BIOSIS, CA, CAPLUS, CIN, IMSDIRECTORY, IPA, PROMT, TOXLINE, TOXLIT, USPATFULL



59 REFERENCES IN FILE CA (1967 TO DATE)
 7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 59 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L6 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2000 ACS (Continued)




● H⁺

CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



14 REFERENCES IN FILE CA (1967 TO DATE)
 14 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L6 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2000 ACS
 RN 60239-18-1 REGISTRY
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid
 CN DOTA
 FS 3D CONCORD
 DR 105416-43-1
 MF C16 H28 N4 O8
 CI COM
 LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOTECHNO, CA, CANCERLIT, CASREACT, CEN, CHEMCATS, CIN, CSCHEM, EMBASE, GMLIN*, MEDLINE, PROMT, TOXLINE, TOXLIT, USPATFULL
 (*File contains numerically searchable property data)



234 REFERENCES IN FILE CA (1967 TO DATE)
 138 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 236 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> fil .search

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	145.46	145.61

FILE 'MEDLINE' ENTERED AT 08:45:45 ON 22 AUG 2000

FILE 'CAPLUS' ENTERED AT 08:45:45 ON 22 AUG 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 08:45:45 ON 22 AUG 2000
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'USPATFULL' ENTERED AT 08:45:45 ON 22 AUG 2000
CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 08:45:45 ON 22 AUG 2000
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

=> d his

(FILE 'HOME' ENTERED AT 08:43:33 ON 22 AUG 2000)

FILE 'REGISTRY' ENTERED AT 08:43:49 ON 22 AUG 2000

L1	STRUCTURE UPLOADED
L2	QUE L1
L3	0 S L2
L4	0 S L2 FULL
	E DOTA/CN
L5	1 S E3
	E DOTA
L6	7 S E3

FILE 'MEDLINE, CAPLUS, BIOSIS, USPATFULL, EMBASE' ENTERED AT 08:45:45 ON 22 AUG 2000

=> s 15 or 16

L7 475 L5 OR L6

=> s 17 and (peptide or peptides)

L8 110 L7 AND (PEPTIDE OR PEPTIDES)

=> s 18 and (linker?)

L9 37 L8 AND (LINKER?)

=> dup rem 19

PROCESSING COMPLETED FOR L9

L10 35 DUP REM L9 (2 DUPLICATES REMOVED)

=> s l9 and (mri or magnetic? or nuclear?)

L11 26 L9 AND (MRI OR MAGNETIC? OR NUCLEAR?)

=> dup rem l11

PROCESSING COMPLETED FOR L11

L12 26 DUP REM L11 (0 DUPLICATES REMOVED)

=> d ibib ab hitstr 1-

YOU HAVE REQUESTED DATA FROM 26 ANSWERS - CONTINUE? Y/(N):y


L12 ANSWER 1 OF 26 USPATFULL
 ACCESSION NUMBER: 2000:91955 USPATFULL
 TITLE: Lipid soluble steroid prodrugs
 INVENTOR(S): Unger, Evan C., Tucson, AZ, United States
 Shen, DeKang, Tucson, AZ, United States
 PATENT ASSIGNEE(S): Imarx Pharmaceutical Corp., Tucson, AZ, United States
 States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6090800	20000718
APPLICATION INFO.:	US 1997-851780	19970506 (8)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Dees, Jose' G.	
ASSISTANT EXAMINER:	Badio, Barbara	
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz Mackiewicz & Norris LLP	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
LINE COUNT:	6285	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel lipid soluble steroid prodrugs comprising steroid prodrugs, and uses of the same.

IT 60239-18-1, 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid
 (charged lipids for drug delivery, imaging, and as contrast agents)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA
 INDEX NAME)



L12 ANSWER 2 OF 26 USPATFULL (Continued)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA
 INDEX NAME)



L12 ANSWER 2 OF 26 USPATFULL
 ACCESSION NUMBER: 2000:91563 USPATFULL
 TITLE: Use of polymerized lipid diagnostic agents
 INVENTOR(S): Li, King Chuen, Stanford, CA, United States
 Bednarski, Mark David, Los Altos, CA, United States
 Storrs, Richard Wood, San Diego, CA, United States
 Li, Henry Y., Visalia, CA, United States
 Tropper, Francois Daniel, Toronto, Canada
 Song, Curtis Kang Hoon, Sunnyvale, CA, United States

States
 Sipkins, Dorothy Anna, Palo Alto, CA, United States
 Kuniyoshi, Jeremy Kenji, Cupertino, CA, United States
 PATENT ASSIGNEE(S): Targesome, Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6090408	20000718
APPLICATION INFO.:	US 1998-122807	19980727 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-629056, filed on 8 Apr 1996 which is a continuation-in-part of Ser. No. US 1994-286555, filed on 5 Aug 1994, now patented,	

Pat. No. US 5512294, issued on 30 Apr 1996

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Kishore, Gollamudi S.
 LEGAL REPRESENTATIVE: Morrison & Foerster LLP
 NUMBER OF CLAIMS: 24
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 37 Drawing Figure(s); 26 Drawing Page(s)
 LINE COUNT: 1530

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polymerized liposome particles which are linked to a targeting agent and may also be linked to a contrast enhancement agent and/or linked to encapsulating a treatment agent. The targeting imaging enhancement polymerized liposome particles interact with biological targets holding the image enhancement agent to specific sites providing in vitro and in vivo study by magnetic resonance, radioactive, x-ray or optical imaging of the expression of molecules in cells and tissues during disease and pathology. Targeting polymerized liposomes may be linked to or encapsulate a treatment agent, such as, proteins, drugs or hormones for directed delivery to specific biological sites for treatment.
 IT 60239-18-1, 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid
 (synthetic lipids prepd. from targeted polymd. liposome contrast agents)

L12 ANSWER 3 OF 26 USPATFULL
 ACCESSION NUMBER: 2000:7398 USPATFULL
 TITLE: Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
 INVENTOR(S): Theodore, Louis J., Lynnwood, WA, United States
 Kasina, Sudhakar, Kirkland, WA, United States
 Reno, John M., Brier, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
 PATENT ASSIGNEE(S): NeoRx Corporation

	NUMBER	DATE
PATENT INFORMATION:	US 6015897	20000118
APPLICATION INFO.:	US 1996-645211	19960513 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-351005, filed on 7 Dec 1994, now abandoned which is a	

continuation-in-part of Ser. No. US 1993-163188, filed on 7 Dec 1993, now abandoned which is a continuation-in-part of Ser.

No. WO 1993-US5406, filed on 7 Jun 1993 which is a continuation-in-part of Ser. No. US 1992-995381,

filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-895588,

filed on 9 Jun 1992, now patented, Pat. No. US 5283342

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Chan, Christina Y.
 ASSISTANT EXAMINER: Gambel, Phillip
 LEGAL REPRESENTATIVE: Seed and Berry LLP
 NUMBER OF CLAIMS: 1
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 12 Drawing Figure(s); 7 Drawing Page(s)
 LINE COUNT: 6303


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. Biotinamido-N-methylglycyl-seryl-O-succinamido-benzyl DOTA is disclosed.

IT 60239-18-1DP, DOTA, biotin conjugates (prepn. of, for tumor pretargeting methodol.)

RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA
 INDEX NAME)

L12 ANSWER 3 OF 26 USPATFULL (Continued)




L12 ANSWER 4 OF 26 USPATFULL

ACCESSION NUMBER: 1999:141269 USPATFULL
 TITLE: Magnetic resonance imaging agents for the detection of physiological agents
 INVENTOR(S): Weade, Thomas, Altadena, CA, United States
 Fraser, Scott, La Canada, CA, United States
 Jacobs, Russell, Arcadia, CA, United States
 Li, Wenhong, Pasadena, CA, United States
 PATENT ASSIGNEE(S): Research Corporation Technologies, Tuscon, AZ, United States (U.S. corporation)
 STATES (U.S. corporation)
 NUMBER DATE
 PATENT INFORMATION: US 5980862 19991109
 APPLICATION INFO.: US 1998-134072 19980813 (9)
 RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-460511, filed on 2 Jun 1995, now abandoned Ser. No. Ser. No. US 1995-486968, filed on 7 Jun 1995, now patented, Pat. No. US 5707605
 And Ser. No. US 971855

NUMBER DATE
 PRIORITY INFORMATION: US 1997-63328 19971027 (60)
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Clardy, S. Mark
 ASSISTANT EXAMINER: Jones, Dameron
 LEGAL REPRESENTATIVE: Flehr Hobbach Test Albritton & Herbert; Trecartin, Esq., Richard F.; Silva, Esq., Robin M.
 NUMBER OF CLAIMS: 33
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 26 Drawing Figure(s); 15 Drawing Page(s)
 LINE COUNT: 2068
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention relates to novel magnetic resonance imaging contrast agents and methods of detecting physiological signals or substances.
 IT 60239-18-1, DOTA (chelator for prepn. of MRI contrast agents)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)


L12 ANSWER 4 OF 26 USPATFULL (Continued)



L12 ANSWER 5 OF 26 USPATFULL

ACCESSION NUMBER: 1999:136685 USPATFULL
 TITLE: Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
 INVENTOR(S): Fritzberg, Alan R., Edmonds, WA, United States
 Abrams, Paul G., Seattle, WA, United States
 Reno, John M., Brier, WA, United States
 Axworthy, Donald B., Brier, WA, United States
 Graves, Scott S., Monroe, WA, United States
 Kasina, Sudhakar, Kirkland, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
 NUMBER DATE
 PATENT INFORMATION: US 5976535 19991102
 APPLICATION INFO.: US 1995-468513 19950606 (8)
 RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-163188, filed on 7 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. WO 1993-US5406, filed on 7 Jun 1993 which is a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5288342
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Cunningham, Thomas M.
 LEGAL REPRESENTATIVE: Seed and Berry LLP
 NUMBER OF CLAIMS: 3
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 13 Drawing Figure(s); 13 Drawing Page(s)
 LINE COUNT: 4278
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Methods for targeting cytotoxins to target sites by administration of a combination of conjugates are provided. Novel cytotoxic combinations for use in such methods are also provided.
 IT 60239-18-1DP, DOTA, biotin conjugates (prepn. of, for tumor pretargeting methodol.)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)

L12 ANSWER 5 OF 26 USPATFULL (Continued)



L12 ANSWER 6 OF 26 USPATFULL

ACCESSION NUMBER: 1999:124468 USPATFULL
 TITLE: Delivery of diagnostic and therapeutic agents to a target site
 INVENTOR(S): Griffiths, Gary L., Morristown, NJ, United States
 Hansen, Hans J., Mystic Island, NJ, United States
 Govindan, Seregunam V., Summit, NJ, United States
 Karacay, Habibe, Clifton, NJ, United States
 PATENT ASSIGNEE(S): Immunomedics, Inc., Morris Plains, NJ, United States
 States
 (U.S. corporation)

NUMBER	DATE
US 5965131	19991012
US 1996-731107	19961009 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-486166, filed on 7 Jun 1995, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Hutzell, Paula K.

ASSISTANT EXAMINER: Worrell, Timothy A.

LEGAL REPRESENTATIVE: Foley & Lardner

NUMBER OF CLAIMS: 26

EXEMPLARY CLAIM: 1

LINE COUNT: 1379

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB An improvement in in vivo pretargeting methods for delivering diagnostic or therapeutic agents to a target site in a mammal uses a clearing agent that binds to the target-binding site of the targeting species, whereby non-bound primary targeting species is cleared from circulation but the clearing agent does not remove the bound primary targeting species. Anti-idiotype antibodies and antibody fragments are preferred clearing agents. Fast clearance is achieved by glycosylating the clearing agent with sugar residues that bind to the hepatic asialoglycoprotein receptor.

IT 60239-18-1, DOTA
 (delivery of diagnostic and therapeutic agents to a target site)

RN 60239-18-1 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)

L12 ANSWER 6 OF 26 USPATFULL (Continued)



L12 ANSWER 7 OF 26 USPATFULL

ACCESSION NUMBER: 1999:113890 USPATFULL

TITLE: Biotinidase resistant biotin-DOTA conjugates

INVENTOR(S): Axworthy, Donald B., Brier, WA, United States
 Theodore, Louis J., Lynnwood, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 Reno, John M., Brier, WA, United States

PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER	DATE
US 5955605	19990921
US 1996-695940	19960812 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-351469, filed on 21 Feb 1995, now patented, Pat. No. US 5608060

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Eisenschenk, Frank C.

LEGAL REPRESENTATIVE: Seed and Berry LLP

NUMBER OF CLAIMS: 10

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 22 Drawing Figure(s); 24 Drawing Page(s)

LINE COUNT: 4727


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Biotinidase-resistant biotin-DOTA conjugates, and methods of use thereof in diagnostic and therapeutic pretargeting methods are provided. These conjugates are useful in diagnosis and treatment of cancer.

IT 60239-18-1DP, DOTA, biotin conjugates
 (prepn. of, for tumor pretargeting methodol.)

RN 60239-18-1 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)




L12 ANSWER 8 OF 26 USPATFULL
 ACCESSION NUMBER: 1999:69701 USPATFULL
 TITLE: Pretargeting methods and compounds
 INVENTOR(S): Azevithy, Donald B., Brier, WA, United States
 Fritzberg, Alan R., Edmonds, VA, United States
 Sandersen, James A., Seattle, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER	DATE
US 5914312	19990622
US 1994-297429	19940826 (8)
Continuation of Ser. No. US 1992-995383, filed on 23 Dec 1992, now abandoned which is a	
continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992,	

now patented, Pat. No. US 5283342
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Eisenschenk, Frank C.
 ASSISTANT EXAMINER: Nolan, Patrick
 LEGAL REPRESENTATIVE: Seed and Berry LLP
 NUMBER OF CLAIMS: 5
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 22 Drawing Figure(s); 22 Drawing Page(s)
 LINE COUNT: 2191

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.
 IT 60239-18-1B, DOTA, biotin conjugates (prepn. of, for tumor pretargeting methodol.)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)


L12 ANSWER 8 OF 26 USPATFULL (Continued)



L12 ANSWER 9 OF 26 USPATFULL
 ACCESSION NUMBER: 1999:69485 USPATFULL
 TITLE: Polychelants containing amide bonds
 INVENTOR(S): Watson, Alan D, Campbell, CA, United States
 PATENT ASSIGNEE(S): Salutar, Inc., Sunnyvale, CA, United States (U.S. corporation)


NUMBER	DATE
US 5914095	19990622
US 1991-772349	19911007 (7)
Continuation-in-part of Ser. No. WO 1990-EP9100565, filed on 5 Apr 1990 And Ser. No. US 1990-464865, filed on 16 Jan 1990, now patented, Pat. No. US 5364613 which is a continuation-in-part of Ser. No. US 1989-335162, filed on 7 Apr 1989, now abandoned	
DOCUMENT TYPE: Utility	
PRIMARY EXAMINER: Hollinden, Gary E.	
LEGAL REPRESENTATIVE: Fish & Richardson P.C.	
NUMBER OF CLAIMS: 23	
EXEMPLARY CLAIM: 1	
LINE COUNT: 1338	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB There are provided polychelants and their metal chelates which are useful in diagnostic imaging and in radiotherapy and which comprise a plurality of macrocyclic chelant moieties, e.g. DOTA residues, conjugated to a dendritic polyamine backbone molecule, e.g. a starburst dendrimer. To produce a site-specific polychelate, one or more of the macrocyclic chelant carrying backbone molecules may be conjugated to a site-directed macromolecule, e.g. a protein.
 IT 60239-18-1D, conjugates with starburst dendritic polymers, metal complexes (for diagnostic imaging and radiotherapy)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L12 ANSWER 9 OF 26 USPATFULL (Continued)

IT 60239-18-1, DOTA (reaction of, with iso-Bu chloroformate)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L12 ANSWER 10 OF 26 USPATFULL
 ACCESSION NUMBER: 1999:66990 USPATFULL
 TITLE: Pretargeting protocols for enhanced localization of active agents to target sites
 INVENTOR(S): Anworthy, Donald B., Brier, WA, United States
 Mallett, Robert W., Seattle, WA, United States
 Hylarides, Mark D., Mukilteo, WA, United States
 Fritzberg, Alan R., Edmonds, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5911969	19990615
APPLICATION INFO.:	US 1994-329617	19941026 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-995381, filed on 23	

Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992,

now patented, Pat. No. US 5283342

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Eisenschenk, Frank C.
 ASSISTANT EXAMINER: Nolan, Patrick J.
 LEGAL REPRESENTATIVE: Seed and Berry LLP

NUMBER OF CLAIMS: 9
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 22 Drawing Figure(s); 22 Drawing Page(s)
 LINE COUNT: 2172

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.


IT 60239-18-1DP, DOTA, biotin conjugates (prepn. of, for tumor pretargeting methodol.)

RN 60239-18-1 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX

NAME)

L12 ANSWER 10 OF 26 USPATFULL (Continued)



L12 ANSWER 11 OF 26 USPATFULL
 ACCESSION NUMBER: 1998:159465 USPATFULL
 TITLE: Methods of treating colon cancer utilizing tumor-specific antibodies
 INVENTOR(S): Welt, Sydney, New York, NY, United States
 Ritter, Gerd, New York, NY, United States
 Cohen, Leonard, New York, NY, United States
 Williams, Jr., Clarence, New York, NY, United States
 States: Richards, Elizabeth Carswell, New York, NY, United States
 John, Mary, New York, NY, United States
 Old, Lloyd J., New York, NY, United States
 PATENT ASSIGNEE(S): Ludwig Institute for Cancer Research, New York, NY, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5851526	19981222
APPLICATION INFO.:	US 1995-449911	19950525 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-20223, filed	

on 16 Feb 1993, now patented, Pat. No. US 5431897

which is a continuation of Ser. No. US 1991-673153,

filed on 18 Mar 1991, now abandoned which is a continuation

of Ser. No. US 1989-327765, filed on 23 Mar 1989, now

abandoned which is a continuation-in-part of Ser.

No. US 1987-118411, filed on 6 Nov 1987, now abandoned

which is a continuation of Ser. No. US 1985-724991,

filed on 19 Apr 1985, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Feisee, Lila

ASSISTANT EXAMINER: Ungar, Susan

LEGAL REPRESENTATIVE: Felfe & Lynch

NUMBER OF CLAIMS: 11

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 17 Drawing Figure(s); 12 Drawing Page(s)

LINE COUNT: 1080

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to methods of reducing the effects of colon cancer tumors. Various agents are conjugated to monoclonal antibodies

which are specific for colon cancer cells. The conjugates are administered to patients having colon cancer such that the effects

of the cancer are reduced.

IT 60239-18-1D, DOTA, antibody and yttrium-90 reaction products

(tumor-specific monoclonal antibody conjugates for treating colon cancer)


RN 60239-18-1 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA

INDEX

NAME)

L12 ANSWER 11 OF 26 USPATFULL (Continued)



L12 ANSWER 12 OF 26 USPATFULL
 ACCESSION NUMBER: 1998:154419 USPATFULL
 TITLE: Production of nitro-benzyl-dota via direct peptide cyclization
 INVENTOR(S): Yau, Eric K., Kirkland, WA, United States
 Theodore, Louis J., Lynnwood, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)


NUMBER	DATE
US 5847121	19981208
US 1995-571816	19951213 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-345811, filed on 22 Nov 1994, now patented, Pat. No. US 5541287 which is a continuation-in-part of Ser. No. US 1993-156565, filed on 22 Nov 1993 which is a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Datlow, Philip I.
 LEGAL REPRESENTATIVE: Seed and Berry LLP
 NUMBER OF CLAIMS: 11
 EXEMPLARY CLAIM: 1,6
 NUMBER OF DRAWINGS: 16 Drawing Figure(s); 16 Drawing Page(s)
 LINE COUNT: 4337

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin, as well as related compounds, are described. Articles of manufacture useful in pretargeting methods are also discussed.
 IT 60239-18-1DP, DOTA, biotin conjugates (prepn. of, for tumor pretargeting methodol.)
 RN 60239-18-1- USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)

L12 ANSWER 12 OF 26 USPATFULL (Continued)




L12 ANSWER 13 OF 26 USPATFULL
 ACCESSION NUMBER: 1998:111959 USPATFULL
 TITLE: Biotinidase-resistant biotinylated compound and methods of use thereof
 INVENTOR(S): Rosebrough, Scott F., Avon, NY, United States
 PATENT ASSIGNEE(S): University of Rochester, Rochester, NY, United States (U.S. corporation)

NUMBER	DATE
US 5807879	19980915
US 1994-221113	19940331 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-845416, filed on 3 Mar 1992, now patented, Pat. No. US 5326778

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Ramauer, Robert W.
 ASSISTANT EXAMINER: Stockton, Laura L.
 LEGAL REPRESENTATIVE: Scully, Scott, Murphy & Presser
 NUMBER OF CLAIMS: 25
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 11 Drawing Figure(s); 6 Drawing Page(s)
 LINE COUNT: 1063

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides biotinylated compounds useful for delivering a molecule to a target site, and methods of making biotinylated compounds. The biotinylated compounds are covalent conjugates of biotin and a diagnostic or therapeutic agent, and are stable to rapid degradation by biotinidase. The compounds of the invention are useful for delivering therapeutic or diagnostic agents to target-bound streptavidin or avidin conjugated cell-targeting agents, including monoclonal antibodies. The compound N-cysteinyl biotin is also provided.
 IT 60239-18-1, DOTA (chelating agent; biotinidase-resistant biotinylated compd.)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)




L12 ANSWER 13 OF 26 USPATFULL (Continued)

L12 ANSWER 14 OF 26 USPATFULL
 ACCESSION NUMBER: 1998:4212 USPATFULL
 TITLE: Magnetic resonance imaging agents for the detection of physiological agents
 INVENTOR(S): Meade, Thomas, Altadena, CA, United States
 Fraser, Scott, Newport Beach, CA, United States
 Jacobs, Russell, Arcadia, CA, United States
 PATENT ASSIGNEE(S): Research Corporation Technologies, Tucson, AZ, United States (U.S. corporation)
 NUMBER DATE

 PATENT INFORMATION: US 5707605 19980113
 APPLICATION INFO.: US 1995-486968 19950607 (8)
 RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-460511, filed on 2 Jun 1995, now abandoned
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Kight, John
 ASSISTANT EXAMINER: Jones, Dameron L.
 LEGAL REPRESENTATIVE: Flehr Hohnbach Test Albritton & Herbert LLP; Trecartin, Richard F.; Silva, Robin M.
 NUMBER OF CLAIMS: 16
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 8 Drawing Figure(s); 7 Drawing Page(s)
 LINE COUNT: 1320
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention relates to magnetic resonance imaging agents comprising a paramagnetic metal ion bound to a complex wherein said complex comprises a chelator and a blocking moiety covalently attached to said chelator which binds in at least a first coordination site of said metal ion and which is capable of interacting with a target substance such that the exchange of water in at least said first coordination site is increased.
 IT 60239-18-1, DOTA (chelator for prepn. of MRI contrast agents)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)


L12 ANSWER 14 OF 26 USPATFULL (Continued)



L12 ANSWER 15 OF 26 USPATFULL
 ACCESSION NUMBER: 97:96997 USPATFULL
 TITLE: Linear oligomeric polychelant compounds
 INVENTOR(S): Love, David B., Wayne, PA, United States
 Dow, William C., Wayne, PA, United States
 Himmelsbach, Richard J., Wayne, PA, United States
 Watson, Alan D., Wayne, PA, United States
 Rocklage, Scott M., Wayne, PA, United States
 PATENT ASSIGNEE(S): Salutar, Inc., Sunnyvale, CA, United States (U.S. corporation)
 NUMBER DATE

 PATENT INFORMATION: US 5679810 19971021
 APPLICATION INFO.: US 1995-480056 19950607 (8)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-86996, filed on 7 Jul 1993, now patented, Pat. No. US 5446146
 which is a division of Ser. No. US 1990-468107, filed on 19 Jan 1990, now patented, Pat. No. US 5281704
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Gupta, Yogendra N.
 LEGAL REPRESENTATIVE: Fish & Richardson PC
 NUMBER OF CLAIMS: 12
 EXEMPLARY CLAIM: 1
 LINE COUNT: 1846
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Linear oligomer polychelant compounds and chelates formed therewith have alternating chelant and linker moieties bound together by amide or ester moieties. The compounds have between 3 and 100 chelant moieties, at least one of which complexes a paramagnetic metal ion. The polychelants and especially their paramagnetic metal polychelates are particularly suitable for diagnostic imaging.
 IT 60239-18-1, 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (prepn. of linear oligomeric polychelant polyaminocarboxylic acids and their paramagnetic metal chelates for diagnostic imaging)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)

L12 ANSWER 15 OF 26 USPATFULL (Continued)



L12 ANSWER 16 OF 26 USPTFULL
 ACCESSION NUMBER: 97:88724 USPTFULL
 TITLE: In vivo agents comprising cationic metal chelators with
 INVENTOR(S): acidic saccharides and glycosaminoglycans
 PATENT ASSIGNEE(S): Ranney, David F., Dallas, TX, United States
 States Access Pharmaceuticals, Inc., Dallas, TX, United States
 (U.S. corporation)

NUMBER	DATE
US 5672334	19970930
US 1993-160085	19931129 (8)
Continuation-in-part of Ser. No. US 1992-880660, filed on 8 May 1992, now abandoned Ser. No. Ser. No. US 1991-863595, filed on 9 Dec 1991, now patented,	
Pat. No. US 5214661 And a continuation-in-part of Ser. No. US 1991-642033, filed on 16 Jan 1991, now patented, Pat. No. US 5336762	
DOCUMENT TYPE: Utility	
PRIMARY EXAMINER: Hollinden, Gary E.	
LEGAL REPRESENTATIVE: Arnold, White & Durkee	
NUMBER OF CLAIMS: 33	
EXEMPLARY CLAIM: 1	
NUMBER OF DRAWINGS: 53 Drawing Figure(s); 53 Drawing Page(s)	
LINE COUNT: 2220	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
AB This application concerns novel agents comprising cationic or chemically basic metal chelators in association with hydrophilic carriers of anionic or chemically acidic saccharides, sulfatoids and glycosaminoglycans. In certain embodiments, the agents comprise metals and metal ions. Covalent and non-covalent chemical and physical means are described for stabilizing the binding of the metal chelators to the carriers. Novel non-covalently bound compositions are described which give uniquely high payloads and ratio of metal chelator to carrier, ranging from a low of about 15% metal chelator by weight, to a characteristic range of 70% to 90% metal chelator by weight.	
Specific embodiments are described comprising deferoxamine, ferrioxamine, iron-basic porphine, iron-triethylenetetraamine, gadolinium DTPA-lysine, gadolinium DOTA-lysine and gadolinium with basic derivatives of porphyrins, porphines, expanded porphyrins, Texaphyrins and sapphyrins	


L12 ANSWER 16 OF 26 USPTFULL (Continued)
 as the basic or cationic metal chelators, which are in turn, bound to acidic or anionic carriers, including one or more of acidic or anionic saccharides, and including sulfated sucrose, pentosan polysulfate, dermatan sulfate, oversulfated dermatan sulfate, chondroitin sulfate, oversulfated chondroitin sulfate, heparan sulfate, beef heparin, porcine heparin, non-anticoagulant heparins, and other native and modified acidic saccharides and glycosaminoglycans.

Also disclosed are methods of enhancing in vivo images arising from induced magnetic resonance signals, methods of enhancing in vivo images in conjunction with ultrasound or X-rays and methods of obtaining in vivo body images utilizing radioisotope containing agents.

Methods of treating vascular disease are also disclosed.

IT 60239-18-1D, DOTA, basic or amine deriva., metal chelates, conjugates with acidic saccharides and glycosaminoglycans (metal-ion chelates with acidic saccharides and glycosaminoglycans, agent prepn., and methods of enhancing MRI imaging)


RN 60239-18-1 USPTFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L12 ANSWER 17 OF 26 USPTFULL
 ACCESSION NUMBER: 97:47507 USPTFULL
 TITLE: Preparation and use of immunoconjugates
 INVENTOR(S): Hansen, Hans J., Mystic Island, NJ, United States
 Leung, Shui-on, Madison, NJ, United States
 Shevitz, Jerry, Livingston, NJ, United States
 Griffiths, Gary L., Morristown, NJ, United States
 Govindan, Seregulam V., Summit, NJ, United States
 PATENT ASSIGNEE(S): Immunomedics, Inc., Morris Plains, NJ, United States
 States (U.S. corporation)

NUMBER	DATE
US 5635603	19970603
US 1994-352715	19941205 (8)
Continuation-in-part of Ser. No. US 1993-162912, filed on 8 Dec 1993, now patented, Pat. No. US 5443953, issued on 22 Aug 1995	
DOCUMENT TYPE: Utility	
PRIMARY EXAMINER: Feises, Lila	
ASSISTANT EXAMINER: Reeves, Julie E.	
LEGAL REPRESENTATIVE: Foley & Lardner	
NUMBER OF CLAIMS: 12	
EXEMPLARY CLAIM: 1	
LINE COUNT: 2541	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
AB The present invention relates to immunoconjugates comprising an antibody fragment which is covalently bound to a diagnostic or therapeutic principle through a carbohydrate moiety in the light chain variable region of the antibody fragment. The invention also relates to immunoconjugates comprising an antibody moiety that is an intact antibody containing a glycosylation site in the light chain variable domain which has been introduced into the antibody by mutating the nucleotide sequence encoding the light chain. The resultant immunoconjugates retain the immunoreactivity of the antibody fragment or intact antibody, and target the diagnostic or therapeutic principle to a target tissue where the diagnostic or therapeutic effect is realized.	
Thus, the invention contemplates the use of such immunoconjugates for diagnosis and immunotherapy. The invention further relates to methods for preparing such immunoconjugates.	
IT 60239-18-1, DOTA (prepn. and use of immunoconjugates)	
RN 60239-18-1 USPTFULL	
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)	

L12 ANSWER 17 OF 26 USPTFULL (Continued)




L12 ANSWER 18 OF 26 USPATFULL
 ACCESSION NUMBER: 97:42628 USPATFULL
 TITLE: Two-step pretargeting methods using improved biotin-active agent conjugates
 INVENTOR(S): Reno, John M., Brier, WA, United States
 Theodore, Louis J., Lynnwood, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)


	NUMBER	DATE
PATENT INFORMATION:	US 5630996	19970520
APPLICATION INFO.:	US 1993-122979	19930916 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned And Ser. No. US 1992-995383, filed on 23 Dec 1992, now abandoned , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Eisenschenk, Frank C.	
LEGAL REPRESENTATIVE:	Burns, Doane, Swecker & Mathis, L.L.P.	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 22 Drawing Page(s)	
LINE COUNT:	4769	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed	
IT	60239-18-IDP, DOTA, conjugate (two-step pretargeting methods using conjugate of antibody and streptavidin or avidin and conjugate of biotin and DOTA radioisotope complex for treating tumor)	
RN	60239-18-1 USPATFULL	
CN	1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)	

L12 ANSWER 19 OF 26 USPATFULL
 ACCESSION NUMBER: 97:36156 USPATFULL
 TITLE: Clearing agents useful in pretargeting methods
 INVENTOR(S): Asworthy, Donald B., Brier, WA, United States
 Reno, John M., Brier, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5624996	19970429
APPLICATION INFO.:	US 1995-462765	19950605 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-163184, filed on 7 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Eisenschenk, Frank C.	
LEGAL REPRESENTATIVE:	Burns, Doane, Swecker & Mathis, L.L.P.	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	3943	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Novel clearing agents are provided which comprise biotin analog containing clearance-directing moieties. Preferably such clearance-directing moieties endogenously contain or a rederivatized to expose galactose and/or mannose residues.	
IT	60239-18-IDP, DOTA, biotin conjugates (prepn. of, for tumor pretargeting methodol.)	
RN	60239-18-1 USPATFULL	
CN	1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)	




L12 ANSWER 18 OF 26 USPATFULL (Continued)



L12 ANSWER 20 OF 26 USPATFULL
 ACCESSION NUMBER: 97:18284 USPATFULL
 TITLE: Biotinidase-resistant biotin-DOTA conjugates
 INVENTOR(S): Asworthy, Donald B., Brier, WA, United States
 Theodore, Louis J., Lynnwood, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 Reno, John M., Brier, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5608060	19970304
APPLICATION INFO.:	WO 9325240	19931223
	US 1995-351469	19950221 (8)
	WO 1993-US5406	19930607
		19950221 PCT 371 date
		19950221 PCT 102(e) date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-995383, filed on 23 Dec 1992, now abandoned And a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342, issued on 1 Feb 1994	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Eisenschenk, Frank C.	
LEGAL REPRESENTATIVE:	Burns, Doane, Swecker & Mathis, L.L.P.	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 22 Drawing Page(s)	
LINE COUNT:	4732	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Biotinidase-resistant biotin-DOTA conjugates, and methods of use thereof in diagnostic and therapeutic pretargeting methods are provided. These conjugates are useful in diagnosis and treatment of cancer.	
IT	60239-18-ID, DOTA, biotin conjugates (biotinidase-resistant biotin-DOTA conjugates for treatment and diagnosis of cancer, (pre)targeting procedures and compns., and compd. prepn. and characterization)	
RN	60239-18-1 USPATFULL	
CN	1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)	


L12 ANSWER 20 OF 26 USPATFULL (Continued)



L12 ANSWER 21 OF 26 USPATFULL
 ACCESSION NUMBER: 96:82819 USPATFULL
 TITLE: Adducts of macrocyclic chelants
 INVENTOR(S): Sieving, Paul F., San Jose, CA, United States
 Watson, Alan D., Campbell, CA, United States
 PATENT ASSIGNEE(S): Nycomed Salutar, Inc., Wayne, PA, United States
 (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5564748	19960910
APPLICATION INFO.:	US 1993-175989	19931230 (8)
RELATED APPL. INFO.:	Division of Ser. No. US 1990-494865, filed on 16 Jan 1990, now patented, Pat. No. US 5364613 which is a continuation-in-part of Ser. No. US 1989-335162, filed on 7 Apr 1989, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Dattlow, Philip I.	
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1172	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	There are provided polychelants and their metal chelates which are useful in diagnostic imaging and in radiotherapy and which comprise a plurality of macrocyclic chelant moieties, e.g. DOTA residues, conjugated to a polyamine backbone molecule, e.g. polylysine. To produce a site-specific polychelate, one or more of the macrocyclic chelant carrying backbone molecules may be conjugated to a site-directed macromolecule, e.g. a protein. For example, adducts of a macrocyclic chelant can be formed by the process of (a) dispersing a carboxylic macrocyclic chelant in a polar, anhydrous solvent, (b) adding a base with a pKa sufficient to remove all carboxyl protons to create an amine salt of the chelant soluble in the solvent, (c) chilling the reaction mixture to between about 5.degree. C. and 55.degree. C. above the freezing point of the solvent, and (d) adding substantial equimolar amount of chilled alkylhaloformate under anhydrous conditions so as to form a slurry containing the mixture carboxycarbonic anhydride of the chelant.	
IT	60239-18-1, DOTA (reaction of, with iso-Bu chloroformate)	
RN	60239-18-1 USPATFULL	
CN	1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX	


L12 ANSWER 21 OF 26 USPATFULL (Continued)



L12 ANSWER 22 OF 26 USPATFULL
 ACCESSION NUMBER: 96:36297 USPATFULL
 TITLE: Targeted polymerized liposome contrast agents
 INVENTOR(S): Li, King C., 21 Ryan Ct., Stanford, CA, United States
 States 94305
 Bednarski, Mark D., 816 Amber La., Los Altos, CA, United States 94024
 Storrs, Richard W., 2755 Rose Bud Ct., Union City, CA, United States 94587
 Li, Henry Y., 3350 W. Sunnyside Ave., Visalia, CA, United States 93277
 Trooper, Francois D., 1851 Magellan Dr., Oakland, CA, United States 94611
 Song, Curtis K. H., 548 E. Maude Ave., Sunnyvale, CA, United States 94086
 Sipkins, Dorothy A., 933 Addison St., Palo Alto, CA, United States 94301
 Kuniyoshi, Jeremy K., 22344 Carta Blanca St., Cupertino, CA, United States 95014

	NUMBER	DATE
PATENT INFORMATION:	US 5512294	19960430
APPLICATION INFO.:	US 1994-286555	19940805 (8)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Kishore, Gollamudi S.	
LEGAL REPRESENTATIVE:	Speckman, Pauley & Fejer	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 19 Drawing Page(s)	
LINE COUNT:	881	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Polymerized liposome particles based upon lipids having a polymerizable functional group and a metal chelator to attach an imaging enhancement agent and lipids having an active targeting group to provide targeted polymerized liposome contrast agents. The polymerized imaging enhancement liposome particles interact with receptor targets holding the image enhancement agent to specific sites providing in vivo study by magnetic resonance, radioactive, x-ray or optical imaging of the expression of molecules in cells and tissues during disease and pathology.	
IT	60239-18-1, 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (synthetic lipids prep. from targeted polyind. liposome contrast agents)	
RN	60239-18-1 USPATFULL	
CN	1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX	

L12 ANSWER 22 OF 26 USPATTFULL (Continued)
NAME)



L12 ANSWER 23 OF 26 USPATTFULL
ACCESSION NUMBER: 95:75864 USPATTFULL
TITLE: Preparation and use of immunoconjugates
INVENTOR(S): Hansen, Hans J., Mystic Island, NJ, United States
Leung, Shui-on, Madison, NJ, United States
Shevitz, Jerry, Livingston, NJ, United States
PATENT ASSIGNEE(S): Immunomedics, Inc., Morris Plains, NJ, United States
(U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5443953	19950822
APPLICATION INFO.:	US 1993-162912	19931208 (8)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Saunders, David	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1692	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to immunoconjugates comprising an antibody

fragment which is covalently bound to a diagnostic or therapeutic principle through a carbohydrate moiety in the light chain variable region of the antibody fragment. The invention also relates to immunoconjugates comprising an antibody moiety that is an intact antibody containing a glycosylation site in the light chain variable domain which has been introduced into the antibody by mutating the nucleotide sequence encoding the light chain. The resultant immunoconjugates retain the immunoreactivity of the antibody fragment or intact antibody, and target the diagnostic or therapeutic principle to a target tissue where the diagnostic or therapeutic effect is realized.

Thus, the invention contemplates the use of such immunoconjugates for diagnosis and immunotherapy. The invention further relates to methods for preparing such immunoconjugates.

IT 60239-18-1P
(prepn. of immunoconjugates as diagnostic and therapeutic agents)
RN 60239-18-1 USPATTFULL
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)

L12 ANSWER 23 OF 26 USPATTFULL (Continued)



L12 ANSWER 24 OF 26 USPATTFULL
ACCESSION NUMBER: 95:33907 USPATTFULL
TITLE: Hybrid magnetic resonance contrast agents
INVENTOR(S): Unger, Evan C., 13365 E. Camino La Cebadilla, Tucson, AZ, United States 85749
Wu, Guanli, 2601 W. Aiden St., Tucson, AZ, United States 85745

	NUMBER	DATE
PATENT INFORMATION:	US 5407657	19950418
APPLICATION INFO.:	US 1994-202807	19940228 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-949691, filed on 22 Sep 1992	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Acquah, Samuel A.	
LEGAL REPRESENTATIVE:	Durando, Antonio R.; Weiss, Harry M.	
NUMBER OF CLAIMS:	87	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1485	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel MRI contrast agents that comprise one or more metal-ion chelates in juxtaposition with one or more free-radical nitroxide compounds in a polymeric or oligomeric molecule. Both the chelate units and the free radical units may, independently, be inside the main chain of the polymer or in a side chain of the linkage portion of the polymer.

The number of combined units of chelates and free radicals in the polymer or oligomer is at least two.

IT 60239-18-1, DOTA
(polymeric mols. contg. chelate moieties and nitroxide moieties as hybrid MRI agents, and their prepn.)

RN 60239-18-1 USPATTFULL
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L12 ANSWER 25 OF 26 USPATFULL
 ACCESSION NUMBER: 94:99669 USPATFULL
 TITLE: Polychelants containing macrocyclic chelant
 moieties
 INVENTOR(S): Sieving, Inul F., 3166 Impala Dr. #5, San Jose, CA,
 United States 95117
 Watson, Alan D., 262A Rincon Ave., Campbell, CA,
 United States 95008
 Quay, Steven C., 428 Oakmead Pkwy., Sunnyvale, CA,
 United States 94086
 Rocklage, Scott M., 255 Cresci Rd., Los Gatos, CA,
 United States 95030

	NUMBER	DATE
PATENT INFORMATION:	US 5364613	19941115
APPLICATION INFO.:	US 1990-464865	19900116 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1989-335162, filed on 7 Apr 1989, now abandoned	

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Michl, Paul R.
 ASSISTANT EXAMINER: Yoon, Tae H.
 LEGAL REPRESENTATIVE: Lyon & Lyon
 NUMBER OF CLAIMS: 33
 EXEMPLARY CLAIM: 1
 LINE COUNT: 1352

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB There are provided polychelants and their metal chelates which are useful in diagnostic imaging and in radiotherapy and which comprise

a plurality of macrocyclic chelant moieties, e.g. DOTA residues, conjugated to a polyamine backbone molecule, e.g. polylysine. To produce a site-specific polychelate, one or more of the macrocyclic chelant carrying backbone molecules may be conjugated to a site-directed macromolecule, e.g. a protein.

IT 60239-18-1D, DOTA, reaction products with amine group-contg. backbone (polychelants contg. macrocyclic chelant moieties for use in radiotherapy and diagnostic imaging)

RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)

L12 ANSWER 25 OF 26 USPATFULL (Continued)



L12 ANSWER 26 OF 26 USPATFULL
 ACCESSION NUMBER: 94:9678 USPATFULL
 TITLE: Biotinylated small molecules
 INVENTOR(S): Gustavson, Linda M., Seattle, WA, United States
 Srinivasan, Ananthachari, St. Charles, MO, United States
 Fritzberg, Alan R., Edmonds, WA, United States
 Reno, John M., Brier, WA, United States
 Anworthy, Donald B., Brier, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5283342	19940201
APPLICATION INFO.:	US 1992-895588	19920609 (7)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Higel, Floyd D.	
NUMBER OF CLAIMS:	4	
EXEMPLARY CLAIM:	1,3	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	911	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described.

IT 60239-18-1DF, DOTA, biotin conjugates (prepn. of, for tumor pretargeting methodol.)

RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)

